中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
CHINESE JOURNAL OF HEPATOBILIARY SURGERY
2010年
6期
443-446
,共4页
沈伟%陶国清%陆培华%李德春%白霞%蔡兵
瀋偉%陶國清%陸培華%李德春%白霞%蔡兵
침위%도국청%륙배화%리덕춘%백하%채병
胰腺肿瘤%DPC4%逆转录病毒%基因治疗%化疗
胰腺腫瘤%DPC4%逆轉錄病毒%基因治療%化療
이선종류%DPC4%역전록병독%기인치료%화료
Pancreatic neoplasms%DPC4%Retroviral vector%Gene therapy%Chemotherapy
目的 运用基因转染技术,观察DPC4基因转染对胰腺癌细胞化疗敏感性的影响.方法 构建表达DPC4基因的逆转录病毒载体,转染胰腺癌细胞BxPC-3,获取稳定表达DPC4的子代胰腺癌的细胞株BxPC-3/DPC4.观察5-Fu、吉西他滨(作用72 h)对胰腺癌细胞的抑制作用.同时应用半定量RT-PCR检测胰腺癌细胞内Mdr-1、Chk1基因的表达情况.结果 DPC4基因转染并稳定表达后,BxPC-3细胞对5-Fu、吉西他滨的IC50浓度(72 h)分别降低了1倍左右.同一浓度下,5-Fu、吉西他滨联合DPC4基因转染对BxPC-3细胞的体外抑制作用也明显增强,癌细胞内的Mdr-1、Chk1基因的mRNA表达明显下调.显示单独使用pLXSN/DPC4、5-Fu、吉西他滨,均能在体外抑制胰腺癌细胞的生长,但pLXSN/DPC4联合化疗药物,对癌细胞生长的抑制作用更为明显.结论 DPC4基因转染能够提高胰腺癌细胞对化疗药物的敏感性,其机制可能是通过下调Mdr-1、Chkl的表达来实现的.
目的 運用基因轉染技術,觀察DPC4基因轉染對胰腺癌細胞化療敏感性的影響.方法 構建錶達DPC4基因的逆轉錄病毒載體,轉染胰腺癌細胞BxPC-3,穫取穩定錶達DPC4的子代胰腺癌的細胞株BxPC-3/DPC4.觀察5-Fu、吉西他濱(作用72 h)對胰腺癌細胞的抑製作用.同時應用半定量RT-PCR檢測胰腺癌細胞內Mdr-1、Chk1基因的錶達情況.結果 DPC4基因轉染併穩定錶達後,BxPC-3細胞對5-Fu、吉西他濱的IC50濃度(72 h)分彆降低瞭1倍左右.同一濃度下,5-Fu、吉西他濱聯閤DPC4基因轉染對BxPC-3細胞的體外抑製作用也明顯增彊,癌細胞內的Mdr-1、Chk1基因的mRNA錶達明顯下調.顯示單獨使用pLXSN/DPC4、5-Fu、吉西他濱,均能在體外抑製胰腺癌細胞的生長,但pLXSN/DPC4聯閤化療藥物,對癌細胞生長的抑製作用更為明顯.結論 DPC4基因轉染能夠提高胰腺癌細胞對化療藥物的敏感性,其機製可能是通過下調Mdr-1、Chkl的錶達來實現的.
목적 운용기인전염기술,관찰DPC4기인전염대이선암세포화료민감성적영향.방법 구건표체DPC4기인적역전록병독재체,전염이선암세포BxPC-3,획취은정표체DPC4적자대이선암적세포주BxPC-3/DPC4.관찰5-Fu、길서타빈(작용72 h)대이선암세포적억제작용.동시응용반정량RT-PCR검측이선암세포내Mdr-1、Chk1기인적표체정황.결과 DPC4기인전염병은정표체후,BxPC-3세포대5-Fu、길서타빈적IC50농도(72 h)분별강저료1배좌우.동일농도하,5-Fu、길서타빈연합DPC4기인전염대BxPC-3세포적체외억제작용야명현증강,암세포내적Mdr-1、Chk1기인적mRNA표체명현하조.현시단독사용pLXSN/DPC4、5-Fu、길서타빈,균능재체외억제이선암세포적생장,단pLXSN/DPC4연합화료약물,대암세포생장적억제작용경위명현.결론 DPC4기인전염능구제고이선암세포대화료약물적민감성,기궤제가능시통과하조Mdr-1、Chkl적표체래실현적.
Objective To observe the effect of DPC4 gene transfection on the chemotherapy sensitivity of pancreatic carcinoma cells. Methods The human DPC4 complementary DNA was subcloned to the retroviral vector pLXSN to obtain recombinant pLXSN/DPC4 with direct inserting potential. The daughter cell BxPC-3/DPC4 which had DPC4 stable expression was acquired after the pancreatic carcinoma BxPC-3 cells had been transfected with pLXSN/DPC4. The sensitivity of the carcinoma cells for 5-Fu and gemcitabine was observed. Meanwhile, the mRNA level of Mdr-1 and Chk1was detected by semi-quantity PCR assay. Results The 50% inhibiting concentrations (IC50)of 5-Fuand gemcitabin4e for BxPC-3 (culturing for 72 h) were rather lower than those of BxPC-3/pLXSN and BxPC-3/-cells. Moreover, the semi-quantity PCR assay revealed that the mRNA level of Mdr-1 and Chk1 was down-regulated. These findings indicated that pLXSN/DPC4 vector, 5-Fu and gemcitabine could inhibit the growth of pancreatic cancer cells. The combined therapy with pLXSN/DPC4 vector and chemotherapeutic drugs could further inhibit the growth of cancer cells. Conclusion The DPC4 gene transfection could enhance the sensitivity of pancreatic cells to chemotherapy, which may be realized through the down-regulation of Mdr-1 and Chk1 gene expression.